Breaking the performance ceiling for neoantigen immunogenicity prediction.

O'Brien, Hugh; Salm, Max; Morton, Laura T; Szukszto, Maciej; O'Farrell, Felix; Boulton, Charlotte; Becker, Pablo D; Samuels, Yardena; Swanton, Charles; Mansour, Marc R; Reker Hadrup, Sine; Quezada, Sergio A

O'Brien, Hugh; Salm, Max; Morton, Laura T; Szukszto, Maciej; O'Farrell, Felix; Boulton, Charlotte; Becker, Pablo D; Samuels, Yardena; Swanton, Charles; Mansour, Marc R; Reker Hadrup, Sine; Quezada, Sergio A.

Afiliação

O'Brien H; Achilles Therapeutics Ltd, London, UK.
Salm M; Achilles Therapeutics Ltd, London, UK. m.salm@achillestx.com.
Morton LT; Achilles Therapeutics Ltd, London, UK.
Szukszto M; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
O'Farrell F; Achilles Therapeutics Ltd, London, UK.
Boulton C; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Becker PD; Achilles Therapeutics Ltd, London, UK.
Samuels Y; Weizmann Institute of Science, Rehovot, Israel.
Swanton C; The Francis Crick Institute, London, UK.
Mansour MR; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Reker Hadrup S; Technical University of Denmark, Lyngby, Denmark. sirha@dtu.dk.
Quezada SA; Achilles Therapeutics Ltd, London, UK. s.quezada@ucl.ac.uk.

Nat Cancer ; 4(12): 1618-1621, 2023 Dec.

Article em En | MEDLINE | ID: mdl-38102360

Assuntos

Antígenos de Neoplasias; Antígenos de Neoplasias/genética; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígenos de Neoplasias Limite: Humans Idioma: En Revista: Nat Cancer Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google